Kornimate/medical-research-clean huggingface dataset:
valuation of the evolution of passive mobility in the spastic upper limb after injection of abobotulinumtoxin(dysport®)

Conditions: Spasticity, Muscle; Stroke Sequelae; Movement Disorders

Summary: assessing the objective measurement of passive joint mobility (rom) in the spastic upper limb with jost's pattern iii in patients with post-stroke spasticity after infiltration with bont-a allows to objectify the increase in passive joint balance (rom).

changes in joint mobility in patients with post-stroke upper limb spasticity after infiltration of botulinum toxin type a. the spasticity pattern that will be evaluated will be pattern number iii based on the classification of jost et al. joint mobility will be measured with the lynx instrument (dycare)

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years. * hemiplegic patients with post-stroke upper limb spasticity affected by pattern iii1 who have undergone at least 2 cycles of previous treatment with bont-a * patients with a mas scale (modified ashworth scale) between 2 and 3 for the affected muscle group; shoulder, elbow, carpus and metacarpophalangeal. * patients with hackett ultrasound qualitative scale between 2 and 3 for the affected muscle group; shoulder, elbow, carpus and metacarpophalangeal. exclusion criteria: * patients who do not wish to sign the informed consent. * prior lack of primary or secondary response to any bont-a for any specific condition or known sensitivity to bont-a or any excipient. * routine or prescribed treatment with any medication that directly or indirectly interferes with neuromuscular function in the last 3 months prior to study botulinum toxin treatment. * having undergone surgery on the muscles, ligaments, tendons, nerves or bones of the limb to be treated. * any medical condition or analytical finding that, in the opinion of the investigator, may compromise compliance with the objectives and / or procedures of the study protocol or exclude the administration of bont-a. * treatment with an investigational new drug in the 4 weeks or 5 half-lives prior to screening to enter the study. * pregnancy.

Keywords: spasticity abobotulinum toxin injection rehabilitation
muscle strengthening exercises and global stretching in elderly

Conditions: Osteoporosis; Senile Osteopenia

Summary: introduction: the life expectancy and the number of people hitting the old age have increased in recent years. the aging process is accompanied by morphological and functional changes that contribute to reduced functional capacity, increase the number of falls and the appearance of physical limitations. exercise promotes maintenance of functional autonomy, improving the physical ability of the elderly making it more independent. objective: to evaluate the effect of a program of muscle strengthening exercises associated with global stretching on balance, fear of falling and functional capacity in elderly women. methods: this was a non-randomized controlled trial, in which 12 volunteers aged over 60 years were divided into two groups: intervention group (ig, n = 7) submitted to muscle strengthening exercises and stretching, 2 times per week for 12 weeks, and the control group (cg, n = 5), not submitted to the protocol but were educated about physical exercises. before and after the protocol were evaluated scores of berg balance scale, the falls efficacy scale international (fes-i) and evaluation of functional autonomy development group for latin american maturity (gdlam). data were statistically analyzed within and between groups with a significance level of p \<0.05.


Eligibility criteria:
inclusion criteria: * women aged over 60 years, * independent in locomotion, * with ability to understand verbal commands to perform the tests and participation in the treatment program exclusion criteria: * execution of other physical activities or doing other types of physical therapy, * had any prior neurological deficit (stroke, traumatic brain injury, parkinson's disease) or * musculoskeletal diseases which compromising performance and mobility, * use of orthosis for locomotion, * inability to perform the evaluation tests and/or participation in the intervention session

Keywords: stretching exercise muscle elderly techniques and exercise physiotherapy
surgical apgar score and modified surgical apgar score

Conditions: Perioperative/Postoperative Complications

Summary: in this study we aimed to define a new modified sas is to predict the incidence of postoperative complication and mortality in major abdominal and orthopedic surgery. we also identify the effectivity of this modified scoring system composed of the duration of operation in addition to the three intraoperative parameters of sas.


Eligibility criteria:
inclusion criteria: * subject has major surgery * more than 18 years exclusion criteria: * pregnant * younger than 18

Keywords: complication mortality modified surgical apgar score
step 6: research study investigating how well semaglutide works in people living with overweight or obesity

Conditions: Overweight; Obesity

Summary: this study will look at the change in participants' body weight from the start to the end of the study. this is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. in addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. participants are three times as likely to get semaglutide as "dummy" medicine. participants will need to take 1 injection once a week. the study medicine is injected with a thin needle in a skinfold in the stomach, thigh or upper arm. the study will last for about one and a half years. participants will have 14 clinic visits and 11 phone calls with the study doctor.


Eligibility criteria:
inclusion criteria: * male or female, age more than or equal to 18 years at the time of signing informed consent * bmi more than or equal to 27.0 kg/m\^2 with more than or equal to 2 weight related comorbidities (treated or untreated) or bmi more than or equal to 35.0 kg/m\^2 with more than or equal to 1 weight related comorbidity (treated or untreated) according to the jasso guideline. at least one comorbidity should be hypertension or dyslipidaemia (japan only: or t2d) * history of at least one self-reported unsuccessful dietary effort to lose body weight * for subjects with t2d at screening (japan only): a) diagnosed with t2d more than or equal to 180 days prior to the day of screening. b) hba1c 7.0-10.0% (53-86 mmol/mol) (both inclusive) exclusion criteria: * a self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records * for subjects without t2d at screening: hba1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening * for subjects with t2d at screening (japan only): a) renal impairment measured as estimated glomerular filtration rate (egfr) value of less than 30 ml/min/1.73 m\^2 (less than 60 ml/min/1.73 m\^2 in subjects treated with sodium-glucose co-transporter 2 inhibitor (sglt2i)) according to chronic kidney disease epidemiology (ckd-epi) creatinine equation as defined by kidney disease improving global outcome (kdigo) 2012 by the central laboratory at screening. b) uncontrolled and potentially unstable diabetic retinopathy or maculopathy. verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and randomisation
systematic transcutaneous oxymetry use in thoracic outlet syndrome

Conditions: Thoracic Outlet Syndrome

Summary: the measurement of the transcutaneous oxygen partial pressure (tcpo2) at exercise is, to our knowledge, the only method to estimate during the exercise the importance of ischemia segment of limb by segment of limb bilaterally and carry on. the diagnosis of thoracic outlet syndrome causing remains difficult and dependent operator in ultrasound because of the risk of false positive (loss of signal) or false negative (insufficient effort, inappropriate movement). our main hypothesis is the existence of significant measurable ischemia in the forearm by transcutaneous oximetry during the maneuvering of the "candlestick". in the event of failure of this maneuver, the other maneuvers such as those of wright, roos, tinel and adson will be realized. in this study we want to evaluate the possibility of using dynamic transcutaneous oximetry as a tool for evaluating ischemia in case of suspicion of thoracic outlet syndrome causing.

patients referred for suspected thoracic outlet syndrome causing and healthy asymptomatic subjects will be included. after signing the consent, the subject will have a clinical and paraclinical examination. age, sex, height, weight, side of clinical symptomatology will be collected. medical history current treatments will also be noted. the examination of transcutaneous oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the "candlestick" (hands up). the most symptomatic arm value in patients and the dominant arm in the control group will be noted. in case of drop between 0 and -25 mmhg, in addition to the maneuvering of the "candlestick", the other maneuvers such as those of wright, roos, tinel and adson will be realized. the results of any additional examinations and / or pre- and post-operative consultations will be collected. subjects complete two quality of life questionnaires: the sf-12 (short form 12) and the dash questionnaire (disabilities of the arm, shoulder and hand). added by an amendment : photoplethysmography has already done its proofs to determine the thoracic outlet syndrome diagnotic. combine with a camera kinect, they should determine the angle of appearance of compression in the 3 dimensions of space.

Eligibility criteria:
inclusion criteria: * subjects referred for investigation of thoracic outlet syndrome causing * affiliation to the french national healthcare system * french speaking patients * ability to stand still for half a minute exclusion criteria: * pregnancy * inability to understand the study goal * patients protected by decision of law

Keywords: transcutaneous oximetry
thyroid functions in children with congenital heart diseases

Conditions: Value of Thyroid Functions in Children With Congenital Heart Diseases

Summary: thyroid hormone is critical for normal neurocognitive development in young infants, and even transient hypothyroidism can cause adverse neurodevelopmental outcomes. in a population of infants with chd who already bear a high risk of long-term developmental delay, detection of hypothyroidism, even of a transient nature, may be even more consequential, and routine periodic monitoring of thyroid function may be necessary to reduce the risk of neurodevelopmental disabilities


Eligibility criteria:
inclusion criteria: * all children since birth up to age of 12 years old including both genders diagnosed to have chd exposed to radiation, contrast or not. exclusion criteria: * above 12 years old
relationship between respiratory functional tests and image thoracic techniques in patients with neuromuscular diseases

Conditions: Amyotrophic Lateral Sclerosis

Summary: it is very important monitoring respiratory muscle function in patients with amyotrophic lateral sclerosis (als). we have at our disposal respiratory functional tests (forced vital capacity (fvc), maximal mouth-inspiratory force (mif), maximal mouth-expiratory force (mef), cough peak expiratory flow (cpef), maximal voluntary ventilation (mvv), arterial blood gases and nocturnal pulsioxymetry) and thoracic image techniques (inspiratory/expiratory thorax x-ray and x-ray scope). but all this explorations present some technique limitations. they are two new methods to explore diaphragmatic function: snif test and diaphragm magnetic resonance imaging (dmri). snif test is simple and easy to be done and it can avoid some problems that have the other respiratory functional test in this kind of patients. dmri seems to correlate with respiratory functional test and it can be useful monitoring diaphragmatic mobility. the objective of our study is to compare and to correlate snif test and dmri with x-ray techniques and respiratory functional tests that measure diaphragmatic force and function. first of all we will study 10 healthy people with a forced spirometry, mif, mef and dmri, trying to obtain diaphragmatic mobility reference values with dmri. lately, we will study patients with als. in the first place, we will perform a transversal study with 30 patients. we will do a forced spirometry, mif, mef, mvv, cpef, snif, arterial blood gases and nocturnal pulsioxymetry, forced inspiratory and expiratory thorax x-ray, diaphragmatic x-ray scope and dmri. secondly, we will perform a prospective study, where we will analyze these variables evolution at 3 and 6 months. we hope we can apply the two new techniques in the future because we think they are simpler, more accurate and more objective to evaluate diaphragmatic mobility.


Eligibility criteria:
inclusion criteria: * amyotrophic lateral sclerosis patients. * clinically stable, at least for one month. exclusion criteria: * claustrophobic patients. * patients using continuous non-invasive ventilation treatment. * incapacity to tolerate supine decubitus. * incapacity to execute respiratory functional tests.

Keywords: diaphragmatic force mobility
descartes-08 for patients with systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus (SLE)

Summary: this is a phase ii study to evaluate the safety, tolerability and manufacturing feasibility of descartes-08 car t-cells in patients with systematic lupus erythematosus (sle).


Eligibility criteria:
inclusion criteria: * patient must be at least 18 years of age. * patient must have systemic lupus erythematosus (sle) at the time of screening. * active symptoms despite recent or ongoing immunosuppressive therapy with glucocorticoids and at least 2 other immunosuppressive medications being tried for at least 12 weeks within 24 months of screening. * at least one of: anti-dsdna, anti-histone, anti-chromatin, and/or anti-sm antibodies detectable at screening as assessed by a clia-certified laboratory. exclusion criteria: * active severe lupus nephritis, active severe cns lupus, and/or neurological symptoms of sle including headache, seizure, psychosis, and organic brain syndrome (a patient with an incidental headache, deemed unrelated to sle, may re-screen by telephone upon resolution of the headache); * major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient. * patient is pregnant or lactating.

Keywords: descartes-08 cart car-t autoimmune auto-antibody auto antibody chimeric antigen receptor t cells lupus sle lupus erythematosus systemic lupus erythematosus le
study of ds-5670a (covid-19 vaccine) in japanese healthy adults and elderly subjects

Conditions: Covid19

Summary: this study will assess the safety, tolerability and immunogenicity of ds-5670a (covid-19 vaccine) and determine the recommended dose in japanese healthy adults and elderly participants.


Eligibility criteria:
inclusion criteria: * japanese citizen * healthy adults aged ≥20 and \<65 years, or healthy elderly aged ≥65 and \<75 years (at the time of informed consent) * body mass index (bmi) is ≥17.5 and \<30.0 kg/m\^2 (at screening) * participants who can follow the compliance requirements during clinical trials, undergo medical examinations and tests specified by the protocol, and report symptoms, etc. exclusion criteria: * have a history of immunodeficiency or having a close relative with congenital immunodeficiency. * have a history of sars-cov-2 infection. * have previously participated in an investigational study of sars-cov-2 vaccine or involving lnps. * have a history of anaphylaxis or severe allergies due to food, cosmetics, medicines, or vaccination * have alcohol or drug dependence. * have a fever of ≥39.0°c or symptoms of suspected allergies such as systemic rash within 2 days after past vaccination, etc.

Keywords: covid-19 prevention sars cov-2 coronavirus vaccine
evaluation of bal procedure with ambu ascope 3 large in patients in an icu setting

Conditions: Atelectasis; Bronchoscopy

Summary: an investigation to determine the single-use scope's ability to suction secretion from the lungs to resolve the collapse of the lung.

the purpose of this investigation it to determine the single-use scope's ability to suction secretion from the lungs to resolve the collapse of the lung. the hypothesis is that ascope 3 large is able to manage the secretion and thereby facilitating the resolution of secretion in the lung.

Eligibility criteria:
inclusion criteria: * patients ≥18 years * clinical indication and eligible for a bal procedure, as judged by the investigator * patients being admitted in the icu at the investigational centre * provision of signed ic by subject, or subject's legal representative e.g. next of kin exclusion criteria: * patients where bal treatment cannot be clinically justified, judged by the investigator * ett \>7 mm and ≤8.5 mm in diameter * participating in other interventional clinical investigations or have previously participated in this investigation
efficacy of human papillomavirus (hpv) vaccination to prevent infection among women living with hiv.

Conditions: Human Papilloma Virus; Hiv

Summary: the efficacy of human papillomavirus (hpv) vaccination to prevent infection among women living with hiv: a prospective, individual, double-blind, randomized controlled study is evaluating immediate or delayed single-dose nonavalent hpv vaccination among women living with hiv who received one hpv vaccination prior to hiv diagnosis.

the hope ii study is an individual-level, randomized trial of immediate or delayed vaccination with a single-dose of the nonavalent hpv vaccine. the primary outcome is single-dose hpv 16/18/31/33/45/52/58 vaccine efficacy (ve). the study will provide evidence on the efficacy of single-dose hpv 16/18/31/33/45/52/58 vaccination among women living with hiv. participants will be randomized 1:1 into two different groups. * group 1: will receive nonavalent hpv vaccine at day 0 and meningococcal vaccine at month 18 * group 2: will receive the meningococcal vaccine at day 0 and nonavalent hpv at month 18 the meningococcal vaccine was chosen as the control vaccination because meningococcal vaccination has no activity against hpv infection. further, the meningococcal vaccine has the potential to be of benefit in a meningitis outbreak context and could be beneficial for young persons in a congregate setting such as tertiary institutions.

Eligibility criteria:
inclusion criteria: 1. assigned female at birth 2. age 16 years and above on the day of signing the informed consent form 3. living with hiv with confirmed test results or clinic records 4. history of receiving a single dose of an hpv vaccine before hiv diagnosis 5. self-reported sexually active in the last six months 6. lives within the study area and willing to provide updated locator information over the course of the study 7. does not have an autoimmune, degenerative, or genetic disease 8. does not have known advanced hiv (as per stage iv world health organization clinical staging criteria for hiv) 9. no other investigator-determined factor would limit participation in the trial 10. has not and is not enrolled in a monoclonal, investigational vaccine, or a large quantity blood draw study 11. the participant has a cervix exclusion criteria: 1. anyone with cervical abnormality on examination 2. anyone with an allergy to vaccine components or yeast
non-invasive assessment of rectum (pouch) by us (rect-us) in a cohort of ibd patients

Conditions: Ulcerative Colitis; Crohn's Disease

Summary: at enrollment, after informed consent form will be discussed and signed, subjects will undergo complete disease assessment. in this study, 150 adult subjects with ibd will be enrolled at the gastroenterology department of the san raffaele hospital (50 patients with crohn's disease, 50 with ulcerative colitis not undergoing proctocolectomy, and 50 with ulcerative colitis undergoing proctocolectomy with ileal pouch-anal anastomosis). all the patients will perform routine investigations with ileocolonoscopy (ic), according to the current standard of care indications and ecco guidelines, and they will be assessed by both intestinal ultrasound (ius) and trans-perineal ultrasound (tpus). blood and stool samples will be obtained for fecal calprotectin (fc) and c-reactive protein (crp) measurements, respectively, as normal clinical practice. all the procedures of this study are performed routinely in clinical practice. all the procedures are performed in a single day-visit for the patient.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of ibd for at least 3 months, in particular 50 with crohn\&;s disease (cd), 50 with ulcerative colitis (uc) not undergoing proctocolectomy, 50 with ulcerative colitis (uc) undergoing proctocolectomy with ileal pouch-anal anastomosis * performing ileocolonoscopy, according to current standards of care and ecco guidelines, will be assessed by both ius and tpus. procedures performed routinely in clinical practice * ability to understand and comply with the study procedure and sign an informed consent form exclusion criteria: * pregnancy; * concomitant intestinal infection (e.g. clostridium difficile); * cirrhosis or intra-abdominal ascites. * subjects not able to comply with any study procedure; * subjects not able to understand and give informed consent form; * subjects with any contraindication to any study procedure.

Keywords: intestinal ultrasound ileocolonoscopy trans-perineal ultrasound
impact of vvv group for veterans with smi

Conditions: Psychotic Disorders; Veterans

Summary: veterans with serious mental illness (smi) struggle with social integration - participation in work, housing, and citizenship - due to symptoms, stigma, and psychosocial challenges. despite considerable va efforts to provide mental health care to veterans with smi, programs that promote social integration are lacking. veterans with smi are at especially high risk for poor social integration and suicidal ideation during the covid-19 pandemic. this project addresses this need with a group-based, peer specialist (ps) co-facilitated psychosocial intervention for veterans with smi, called "veteran voices and visions" (vvv). vvv targets veterans with smi who experience psychosis, a group particularly in need of support with social integration. virtual vvv groups are co-led by va mental health clinicians (mhcs) and pss via online video conference. the approach facilitates group cohesion around and normalization of the common psychotic symptoms of smi: hallucinations, delusions, and social isolation. this intervention has the potential to create and foster a supportive community that improves the social integration of participants by reducing their distress and self-stigma, and increasing self-efficacy.


Eligibility criteria:
inclusion criteria: * dsm 5 diagnoses of schizophrenia, schizoaffective disorder, bipolar with psychosis, depression with psychosis, unspecified psychosis exclusion criteria: * substance-induced psychosis, * clinically significant neurological disease, * history of serious head injury with loss of consciousness \> 1 hour.